logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Zymogenetics, Inc.


USPTO Granted Patents = 723



Trademarks = 1

Forward Citations = 9,725

Loading Chart...
Loading Chart...

287 inventors (with patents filed for the assignee):

goldMedal Paul O Sheppard (143 out of 163 patents)

silverMedal Scott R Presnell (118 out of 129 patents)

bronzeMedal Wayne R Kindsvogel (72 out of 104 patents)

4.  Darrell C Conklin (63 out of 63 patents)

5.  Cindy A Sprecher (61 out of 65 patents)

6.  Donald C Foster (60 out of 72 patents)

7.  Stephen R Jaspers (54 out of 56 patents)

8.  Jane A Gross (51 out of 52 patents)

9.  Julia E Novak (50 out of 56 patents)

10.  Wenfeng Xu (48 out of 48 patents)

11.  Brian A Fox (46 out of 49 patents)

12.  Janine M Bilsborough (45 out of 54 patents)

13.  Kevin M Klucher (45 out of 45 patents)

14.  Paul D Bishop (42 out of 59 patents)

15.  Angela K Hammond (42 out of 42 patents)


Core Competencies:
IL-31 Monoclonal Antibodies
Anti-IL-31RA Antibodies
Bispecific Antibodies
Neuronal Inflammation
Pruritic Disease Treatments
ZCYTOR17 Cytokine Receptor
IL-17A and IL-17F Antibodies
Systemic Lupus Erythematosus
Atopic Dermatitis
Inflammatory Disease Treatments
Polynucleotides Encoding Antibodies
Signal Transduction Antagonists

723 patents:

1. 11542327 - Methods of treating pruritic disease with IL-31 monoclonal antibodies (2023-01-03),
2. 11312779 - Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions (2022-04-26),
3. RE48370 - Levels of BCMA protein expression on B cells and use in methods of treating systemic lupus erythematosus (2020-12-28),
4. 10640575 - Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases (2020-05-05),
5. 10640559 - Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies (2020-05-05),
6. 10611846 - Methods of treating skin disorders using anti-IL-31RA antibodies (2020-04-07),
7. 10570187 - Soluble hybrid Fcγ receptors and related methods (2020-02-25),
8. 10562967 - Treating inflammation with IL-17/IL-23 bispecific antibodies (2020-02-18),
9. 10434173 - Use of IL-31 monoclonal antibodies for treating pruritus (2019-10-08),
10. 10273297 - Use of IL-31 monoclonal antibodies for reducing pruritus (2019-04-30),
11. 10259868 - Methods of treating atopic dermatitis with IL-31 monoclonal antibodies (2019-04-16),
12. 10227415 - Methods of producing a zcytor17 heterodimeric cytokine receptor (2019-03-12),
13. 10023656 - Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies (2018-07-17),
14. 10005837 - B7 family member zB7H6 and related compositions and methods (2018-06-26),
15. 10000563 - Monoclonal antibodies that bind both IL-17A and IL-17F (2018-06-19),
Zymogenetics, Inc. is a biotechnology company focused on the development of innovative therapies for the treatment of various diseases. They specialize in the discovery and development of protein-based therapeutics to address unmet medical needs. With a strong emphasis on research and development, Zymogenetics is dedicated to advancing cutting-edge treatments that can improve the lives of patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

723 Patents

#3 in Seattle, WA

#10 in Washington

#679 in US

#1,347 in the World

...
Seattle, WA, United States of America

Zymogenetics, Inc.

Forward Citations = 9,725

287 inventors:

goldMedal Paul O Sheppard (143 out of 163 patents)

silverMedal Scott R Presnell (118 out of 129 patents)

bronzeMedal Wayne R Kindsvogel (72 out of 104 patents)

4.  Darrell C Conklin (63 out of 63 patents)

5.  Cindy A Sprecher (61 out of 65 patents)

Please report any incorrect information to support@idiyas.com
Loading…